ASCO 2026: Novel CD5 directed CAR-T therapy for T-ALL/PTCL shows mixed response

Phase I CONQUER results showed high efficacy for the cell therapy, but with high rates of infection in tow. Successful in B-cell blood cancers, CAR-T therapies have failed to demonstrate the same efficacy in T-cell malignancies. Credit: Nemes Laszlo/Shutterstock.com Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma (PTCL) represent a group with a notable absence of targeted therapy options. Current treatments depend entirely on combination chemotherapy, after which approximately 60% of first-line patients progress to refractory or relapsed (R/R) disease and are in need of stem cell transplantation (HCT). While chimeric antigen receptor…

Source: Clinical Trials Arena